Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Serum osteoprotegerin as an early marker of chronic kidney disease in hypertensive patients

The Egyptian Journal of Internal Medicine volume 31, pages 922–926 (2019)Cite this article

Abstract

Background

Serum osteoprotegerin (OPG) is a marker of cardiovascular disease. The deterioration of renal function in diabetic patients could be predicted by OPG concentrations, and it was suggested that OPG could be used as a risk marker for chronic kidney disease (CKD) in patients with hypertension.

Objective

The aim was to investigate the role of serum OPG as an early marker of CKD in hypertensive patients.

Patients and methods

A total of 144 hypertensive patients were included and classified into two main groups: group I, which included 72 hypertensive patients without CKD [estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m2], and group II, which included 72 hypertensive patients with CKD (eGFR<60 ml/min/1.73 m2). All participants of the study were subjected to detail clinical examination and investigations including complete blood count, fasting and random blood glucose, glycosylated hemoglobin, urine analysis, serum creatinine, liver function tests, eGFR, and serum OPG assays.

Results

Serum OPG levels were significantly higher in hypertensive group with CKD than in hypertensive group without CKD. A significant positive correlation was found between OPG and diastolic blood pressure, duration of hypertension, serum creatinine, and albumin creatinine ratio, whereas there is a negative correlation between OPG and both weight and eGFR. The best cutoff value of serum OPG in prediction of CKD among hypertensive patients is greater than 1.9 ng/ml with sensitivity of 100% and specificity of 100%.

Conclusion

Serum OPG can serve as an early marker for CKD in hypertensive patients.

References

  1. The Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 3:1–150.

    Article  Google Scholar 

  2. Albalawi AMA, Ahmed M, Alharbi AAH, Almansour ADM, AlSogair AAA. Awareness of chronic kidney disease in Hail Region. Egypt J Hosp Med 2018; 71:3634–3640.

    Google Scholar 

  3. Murray Christopher JL, Forouzanfar Mohammad H, Lopez Alan D. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388:1659–1724.

    Article  Google Scholar 

  4. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007; 282:31601–31609.

    Article  CAS  Google Scholar 

  5. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/ RANK system for bone and vascular diseases. JAMA 2004; 292:490–495.

    Article  CAS  Google Scholar 

  6. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55:2049–2061.

    Article  CAS  Google Scholar 

  7. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010; 30:1849–1854.

    Article  CAS  Google Scholar 

  8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461–470.

    CAS  PubMed  Google Scholar 

  9. Ahluwalia M, Bangalore S. Management of hypertension in 2017: targets and therapies. Curr Opinion Cardiol 2017; 32:413–421.

    Article  Google Scholar 

  10. Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011; 7:11–21.

    Article  Google Scholar 

  11. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 2017; 389:1238–1252.

    Article  Google Scholar 

  12. Rysz J, Gluba-Brzózka A, Franczyk B, Jabłonowski Z, Ciałkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci 2017; 18:1702–1718.

    Article  Google Scholar 

  13. Lewis JR, Lim WH, Zhu K, Wong G, Dhaliwal SS, Lim EM, et al. Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study. Am J Nephrol 2014; 39:66–74.

    Article  CAS  Google Scholar 

  14. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86:631–637.

    CAS  PubMed  Google Scholar 

  15. Bernardi S, Toffoli B, Bossi F, Candido R, Stenner E, Carretta R, et al. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017; 18:219.

    Article  Google Scholar 

  16. Vik A, Brodin EE, Mathiesen EB, Brox J, Jørgensen L, Njølstad I, et al. Serum osteoprotegerin and renal function in the general population: the Tromsø Study. Clin Kidney J 2017; 10:38–44.

    CAS  PubMed  Google Scholar 

  17. Demir P, Erdenen F, Aral H, Turker Emre T, Kose S, Altunoglu E. Serum osteoprotegerin levels related with cardiovascular risk factors in chronic kidney disease. J Clin Lab Anal 2016; 30:811–817.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt

    Khaled A. Elhefnawy MD, Ezzat M. Mohamed & Hala M. Allam

  2. Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Abeer A. Fikry

  3. Department of Internal Medicine, Shebin Elkom Fever Hospital, Shebin Elkom, Egypt

    Athar M. Abou Yousef

Authors
  1. Khaled A. Elhefnawy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ezzat M. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Athar M. Abou Yousef
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abeer A. Fikry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hala M. Allam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Khaled A. Elhefnawy MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elhefnawy, K.A., Mohamed, E.M., Abou Yousef, A.M. et al. Serum osteoprotegerin as an early marker of chronic kidney disease in hypertensive patients. Egypt J Intern Med 31, 922–926 (2019). https://doi.org/10.4103/ejim.ejim_169_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_169_19

Keywords